Amy Tapper

Amy Tapper has over 20 years of experience in the pharmaceutical industry. Amy began their career in 1995 as a Councilor for the Northeastern Section of the American Chemical Society. In 2001, they joined Genzyme as a Staff Scientist I, where they developed a process for a small molecule candidate for a neurodegenerative disease and expanded and diversified Genzyme's chemical library. In 2004, they joined Peptimmune as an Associate Director, where they researched, developed, and transferred chemical processes to pilot plant for large scale production of pre-clinical and clinical candidates. In 2007, they joined Momenta Pharmaceuticals as a Principal Scientist, where they were the drug substance coordinator for a novel anticoagulant compound for acute coronary syndrome (ACS) and managed cGMP manufacturing campaigns to support on-going clinical studies. In 2008, they joined Ferrokin BioSciences as a Senior Vice President. In 2012, they joined Shire Pharmaceuticals as a Consultant and also joined Imago BioSciences as a Senior Vice President. In 2022, they were promoted to Chief Technology Officer at Imago BioSciences, Inc.

Amy Tapper began their education in 1988 when they attended Boston College and earned a B.S. in Chemistry. Amy then continued their education at Boston University, where they earned a Ph.D. in Chemistry in 2001.